| abstract |
Products and methods to inhibit anthrax toxin, e.g., in conjunction with antibiotic treatment to eradicate B. anthracis organisms, are provided. The products can bind anthrax toxin subunits directly, or, alternatively elicit an anti-anthrax toxin response. Preferred products are immunoglobulin-derived variant constructs or synthebodies that carry anthrax toxin-binding sequences. Methods of using such immunoglobulin-derived variants for treating anthrax infection are provided. |